|

DC/MM Fusion Vaccine Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Also known as: Dendritic Cell and Tumor Fusion Vaccine, Dendritic Cell/Tumor Fusion Vaccine

Pipeline

Phase 1: 2

Top Sponsors

  • David Avigan2

Indications

  • Relapse Multiple Myeloma2
  • Refractory Multiple Myeloma2
  • Multiple Myeloma2
  • Cancer2

Boston, Massachusetts2 trials

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Beth Israel Deaconess Medical Center

Phase 1
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Beth Israel Deaconess Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.